MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
+4.84%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$704M
AUM Growth
+$704M
(+5.7%)
Cap. Flow
+$129M
Cap. Flow
% of AUM
18.31%
Top 10 Holdings %
Top 10 Hldgs %
44.68%
Holding
54
New
11
Increased
21
Reduced
11
Closed
7
Top Buys
| 1 |
Zai Lab
ZLAB
|
$21M |
| 2 |
Scholar Rock
SRRK
|
$18M |
| 3 |
PTC Therapeutics
PTCT
|
$15.6M |
| 4 |
Context Therapeutics
CNTX
|
$15.4M |
| 5 |
Replimune Group
REPL
|
$11.5M |
Top Sells
| 1 |
Insmed
INSM
|
$15.6M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$15.4M |
| 3 |
KalVista Pharmaceuticals
KALV
|
$10.4M |
| 4 |
Viking Therapeutics
VKTX
|
$7.66M |
| 5 |
Intellia Therapeutics
NTLA
|
$5.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$445M
| $93.2M | 13.23% | 7,648,268 | – | – |
|
2
Crinetics Pharmaceuticals
CRNX
$2.92B
| $31.5M | 4.48% | 617,035 +91,190 | +17% | +$4.66M |
|
3
Edgewise Therapeutics
EWTX
$1.51B
| $28.8M | 4.09% | 1,079,316 +162,150 | +18% | +$4.33M |
|
|
4
Insmed
INSM
$28.8B
| $26.9M | 3.82% | 389,611 -225,780 | -37% | -$15.6M |
|
5
Natera
NTRA
$23.1B
| $25.4M | 3.61% | 160,626 -16,473 | -9% | -$2.61M |
|
6
Mirum Pharmaceuticals
MIRM
$3.71B
| $24.4M | 3.46% | 589,579 +96,856 | +20% | +$4M |
|
7
Disc Medicine
IRON
$2.07B
| $22M | 3.12% | 346,401 +34,640 | +11% | +$2.2M |
|
8
Lantheus
LNTH
$3.73B
| $21.1M | 3% | 236,213 +86,031 | +57% | +$7.7M |
|
|
9
Zai Lab
ZLAB
$3.68B
| $21M | 2.97% | +800,000 | New | +$21M |
|
10
Avidity Biosciences
RNA
$5.99B
| $20.4M | 2.9% | 702,981 +14,006 | +2% | +$407K |
|
11
Iovance Biotherapeutics
IOVA
$807M
| $19.8M | 2.81% | 2,673,905 +267,191 | +11% | +$1.98M |
|
|
12
PTC Therapeutics
PTCT
$3.92B
| $19.6M | 2.79% | 434,767 +345,052 | +385% | +$15.6M |
|
13
Wave Life Sciences
WVE
$1.53B
| $18.4M | 2.62% | 1,489,237 +864,766 | +138% | +$10.7M |
|
|
14
Scholar Rock
SRRK
$3.14B
| $18M | 2.55% | +416,144 | New | +$18M |
|
15
MoonLake Immunotherapeutics
MLTX
$3.54B
| $17.1M | 2.42% | 315,230 -33,833 | -10% | -$1.83M |
|
16
Olema Pharmaceuticals
OLMA
$375M
| $17M | 2.41% | 2,912,550 +231,954 | +9% | +$1.35M |
|
17
Ultragenyx Pharmaceutical
RARE
$2.89B
| $16.5M | 2.34% | 391,018 +61,285 | +19% | +$2.58M |
|
|
18
Context Therapeutics
CNTX
$75.4M
| $15.4M | 2.19% | +14,705,882 | New | +$15.4M |
|
19
Guardant Health
GH
$8.41B
| $13.8M | 1.96% | 452,739 -46,431 | -9% | -$1.42M |
|
20
Revolution Medicines
RVMD
$7.1B
| $13.7M | 1.95% | 313,817 +22,426 | +8% | +$981K |
|
21
iTeos Therapeutics
ITOS
| $13.4M | 1.9% | 1,745,943 | – | – |
|
22
Cartesian Therapeutics
RNAC
$261M
| $12.9M | 1.83% | 721,139 +91,716 | +15% | +$1.64M |
|
23
Rocket Pharmaceuticals
RCKT
$354M
| $12.8M | 1.82% | 1,020,559 -45,814 | -4% | -$576K |
|
24
Akero Therapeutics
AKRO
$3.74B
| $12.8M | 1.82% | 460,617 +68,073 | +17% | +$1.89M |
|
25
Trevi Therapeutics
TRVI
$883M
| $12.8M | 1.81% | 3,094,896 +1,556,379 | +101% | +$6.41M |
|